| abstract |
The present invention relates to quinazoline derivatives of formula I and their salts, their preparation, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as an active ingredient: , M is an integer of 1-2; R 1 is hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, or -NR 5 R 6 (wherein, R 5 and R 6 are obtained is at or different things are the same, each represents hydrogen or C 1-3 alkyl) represents; R 2 is hydrogen, hydroxy, halogeno X represents methoxy, amino or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkinoyloxy, trifluoromethyl, cyano, amino or nitro; X 1, -O -, - CH 2 - , - S -, - SO -, - SO 2 -, - NR 7 CO -, - C ONR 8 -, - SO 2 NR 9 -, - NR 10 SO 2 -, or -NR 11 - (wherein, R 7, R 8, R 9, R 10 and R 11 are each independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy C 2-3 alkyl); R 4 is a 5- or 6-membered ring optionally substituted saturated carbocyclic or heterocyclic group, or alkenyl, alkynyl Or an optionally substituted alkyl group, wherein the alkyl group can include a heteroatom linking group, wherein the alkenyl, alkynyl, or alkyl group is alkyl and a 5- or 6-membered saturated carbocycle or It may have a terminal optionally substituted group selected from a heterocyclic group. Compounds of Formula I and pharmaceutically acceptable salts thereof inhibit the effects of VEGF as a valuable property in treating a number of disease states, including cancer and rheumatoid arthritis. |